Predictors of Mortality of Oncological Patients Admitted in the Pediatric ICU of a Tertiary Reference Hospital
Ynnaiana Navarro De Lima Santana Quintans,
Denise Bousfield Da Silva,
Nilzete Liberato Bresolin,
Joana Sacheti Freitas
Issue:
Volume 9, Issue 3, September 2021
Pages:
45-49
Received:
2 June 2021
Accepted:
22 June 2021
Published:
9 July 2021
Abstract: Cancer in the childhood and adolescence age group is considered rare. Despite this, the incidence of new diagnoses is increasing every day, as well as an increase in the cure rate, which is due, among other reasons, to the intensification of cancer treatment. As a consequence, these patients end up needing intervention in intensive care units (ICU). When compared to other patients, the mortality rate of cancer patients was higher than the general mortality in the pediatric ICU. For this reason, it is important to identify prognostic factors that can guide the early admission of these patients to the ICU. This study evaluated several variables related to the cancer patient admitted to the ICU, correlating them with the clinical outcome. Some variables were identified that increased the risk of the patient presenting with death as outcome, namely the number of organic dysfunctions on admission, the use of cardiotoxic chemotherapy, the use of nephrotoxic medications and the number of interventions performed on the patient in the first hours in the ICU. It is hoped that with this article, teams that provide health care to pediatric cancer patients will be able to identify children and adolescents in need of ICU interventions earlier, thus increasing their survival rate.
Abstract: Cancer in the childhood and adolescence age group is considered rare. Despite this, the incidence of new diagnoses is increasing every day, as well as an increase in the cure rate, which is due, among other reasons, to the intensification of cancer treatment. As a consequence, these patients end up needing intervention in intensive care units (ICU)...
Show More
Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years
Jong-Hwa Lee,
Joo-Yeon Gie,
Yoo-Jin Cho,
Chul-Soo Kim,
Myung-Seup Chae,
Euishin Edmund Kim,
Wang-Jae Lee,
U-Hyun Park,
Thomas Lau,
Josef Sotckenreiter,
Stefan Woehrer,
Karl Postbauer
Issue:
Volume 9, Issue 3, September 2021
Pages:
50-55
Received:
28 May 2021
Accepted:
17 June 2021
Published:
19 July 2021
Abstract: SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.
Abstract: SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important componen...
Show More
